ResMed Inc. (RMD): Price and Financial Metrics

ResMed Inc. (RMD): $183.10

2.81 (+1.56%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

RMD Price/Volume Stats

Current price $183.10 52-week high $243.52
Prev. close $180.29 52-week low $132.24
Day low $179.01 Volume 706,100
Day high $183.51 Avg. volume 909,156
50-day MA $177.63 Dividend yield 1.06%
200-day MA $179.64 Market Cap 26.93B

RMD Stock Price Chart Interactive Chart >

RMD POWR Grades

  • RMD scores best on the Quality dimension, with a Quality rank ahead of 61.79% of US stocks.
  • The strongest trend for RMD is in Growth, which has been heading down over the past 26 weeks.
  • RMD ranks lowest in Momentum; there it ranks in the 4th percentile.

RMD Stock Summary

  • RESMED INC's market capitalization of $24,386,367,759 is ahead of 90.57% of US-listed equities.
  • Price to trailing twelve month operating cash flow for RMD is currently 26.08, higher than 83.79% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 60.71%, RESMED INC's debt growth rate surpasses 88.21% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to RESMED INC, a group of peers worth examining would be LOGI, HOLX, A, EMN, and HXL.
  • Visit RMD's SEC page to see the company's official filings. To visit the company's web site, go to www.resmed.com.

RMD Valuation Summary

  • In comparison to the median Healthcare stock, RMD's price/earnings ratio is 4.29% lower, now standing at 27.9.
  • Over the past 243 months, RMD's price/sales ratio has gone up 1.

Below are key valuation metrics over time for RMD.

Stock Date P/S P/B P/E EV/EBIT
RMD 2023-12-29 5.8 6.0 27.9 22.8
RMD 2023-12-28 5.8 6.0 28.1 22.9
RMD 2023-12-27 5.8 6.0 28.1 22.9
RMD 2023-12-26 5.8 6.0 28.1 23.0
RMD 2023-12-22 5.8 5.9 27.8 22.7
RMD 2023-12-21 5.9 6.0 28.4 23.1

RMD Growth Metrics

    The 4 year net income to common stockholders growth rate now stands at 53.62%.
  • The 4 year price growth rate now stands at 133.96%.
  • Its year over year cash and equivalents growth rate is now at -12.52%.
Over the past 52 months, RMD's revenue has gone up $1,358,459,000.

The table below shows RMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 3,763.275 370.223 809.465
2022-09-30 3,624.405 461.466 786.302
2022-06-30 3,578.127 351.147 779.437
2022-03-31 3,539.492 498.186 779.476
2021-12-31 3,443.759 577.025 521.983
2021-09-30 3,348.896 527.062 499.746

RMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • RMD has a Quality Grade of C, ranking ahead of 68.39% of graded US stocks.
  • RMD's asset turnover comes in at 0.72 -- ranking 50th of 186 Medical Equipment stocks.
  • PEYE, MMSI, and SIEN are the stocks whose asset turnover ratios are most correlated with RMD.

The table below shows RMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.720 0.569 0.426
2021-06-30 0.691 0.575 0.410
2021-03-31 0.673 0.582 0.379
2020-12-31 0.676 0.582 0.342
2020-09-30 0.670 0.583 0.321
2020-06-30 0.672 0.581 0.300

RMD Price Target

For more insight on analysts targets of RMD, see our RMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $261.67 Average Broker Recommendation 1.91 (Hold)

ResMed Inc. (RMD) Company Bio


ResMed is a San DiegoCalifornia-based medical device company. It primarily provides cloud-connectable CPAP devices and masks for the treatment of sleep apnea, as well as devices and masks for treating chronic obstructive pulmonary disease (COPD), neuromuscular disease, and other respiratory-related conditions. It also provides a self-monitoring digital sensor and app for people who use inhalers to treat COPD or asthma via Propeller Health, which ResMed acquired in 2019. (Source:Wikipedia)  


RMD Latest News Stream


Event/Time News Detail
Loading, please wait...

RMD Latest Social Stream


Loading social stream, please wait...

View Full RMD Social Stream

Latest RMD News From Around the Web

Below are the latest news stories about RESMED INC that investors may wish to consider to help them evaluate RMD as an investment opportunity.

ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer and chair of the board, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, beginning at approximately 2:15 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resmed.com. The

Yahoo | December 27, 2023

Resmed posts notice about risk of mask magnets interfering with medical implants

Like its rival Philips, Resmed has determined that patients should not wear magnetized masks near some implants.

Yahoo | December 22, 2023

ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices

ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for UseSAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential magnetic interference when magnets are near certain implants and medical devices in the body. This voluntary field correction does not require a return of a mask with magnets unless the patient is contr

Yahoo | December 20, 2023

Resmed hails ‘significant victory’ as patent board rules in dispute with NYU

The decisions invalidate claims that NYU argued were infringed by Resmed’s sleep apnea devices.

Yahoo | December 14, 2023

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.

Yahoo | December 12, 2023

Read More 'RMD' Stories Here

RMD Price Returns

1-mo 6.86%
3-mo 19.29%
6-mo 14.39%
1-year -13.96%
3-year -6.16%
5-year 89.08%
YTD 6.71%
2023 -16.55%
2022 -19.47%
2021 23.41%
2020 38.33%
2019 37.85%

RMD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RMD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!